Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1~* Patients with acceptable renal, hepatic, and bone marrow function~Exclusion Criteria:~* Symptomatic and/or unstable brain metastases,~* Any cancer treatment within 4 weeks from study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): Carboplatin plus PF-01367338
- ARM A EXPANSION (Type: EXPERIMENTAL): Carboplatin plus PF-01367338

Based on this trial design, predict the completion outcome and termination type (if applicable).